SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Elvis Presley

PatientElvis Presley
Date of birth1987-01-08
IdentifiersMRN HR-ML003-SYN; SSN (made up) 000-03-4417
Document date2026-10-28
AuthorColeman Ashby-Nakagawa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-month review after the tour. [S]

History of Present Illness

Mr. Presley returns two weeks after finishing a three-week tour. He kept every weekly video visit on tour. He has taken buprenorphine 16 mg every morning with rare cravings and no other opioid, and diazepam 32 mg a day without withdrawal symptoms; he sleeps about seven hours with CPAP, on 88% of nights, and his Epworth score is 6. His home blood pressure averages 122/78. On tirzepatide 5 mg weekly for five weeks he has had mild nausea once and no constipation, and his weight is 102.6 kg. His bowels open daily or every other day on polyethylene glycol. He has no eye symptoms. He has started walking each morning and eating his main meal before the show. [S]

ElementDetail
Buprenorphine16 mg daily; rare cravings; no other opioid
Diazepam32 mg a day for five weeks; no withdrawal symptoms
Weight102.6 kg, down 6.4 kg (5.9%) from intake
Blood pressureHome average 122/78
CPAP88% of nights; Epworth 6
Liver testsALT 44, AST 33, GGT 55 U/L, now normal

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight down
GastrointestinalNegativeNausea once; bowels regular
EyesNegativeNo pain, halos or vision change
PsychiatricNegativePHQ-9 4; no thoughts of suicide or self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultationUp to five tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultationUp to three tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a timeOne tablet three times daily; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a timeUp to three tablets a day; seven-day supplyOral route2026-07-10 to 2026-07-17completedS
Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucomaStoppedOral route2026-07-10 to 2026-07-10completedS
Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologistOne drop in each eye at bedtimeOphthalmic route2026-07-10activeS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bagOne spray for a suspected overdose; call 911Nasal route2026-07-10activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g in water once dailyOral route2026-07-10activeS
Senna 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route2026-07-10 to 2026-08-07completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic onlyTwo films once daily, or one film twice dailySublingual route2026-07-17activeS
Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stableOne tablet four times daily; seven-day supplyOral route2026-07-17 to 2026-08-07completedS
Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a timeOne tablet three times daily with the 2 mg tablets as scheduledOral route2026-08-07activeS
Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg)Per the written taper scheduleOral route2026-08-07 to 2026-10-28completedS
Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-07-17activeS
Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly2.5 mg once weeklySubcutaneous route2026-08-07 to 2026-09-23completedS
Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly5 mg once weeklySubcutaneous route2026-09-23activeS
Naproxen 500 mg oral tablet, one tablet twice daily with food for five daysOne tablet twice daily with food for five daysOral route2026-09-09 to 2026-09-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-28Body height183cmS
2026-10-28Body weight102.6kgS
2026-10-28Body mass index (BMI) [Ratio]30.6kg/m2S
2026-10-28Systolic blood pressure122mm[Hg]S
2026-10-28Diastolic blood pressure78mm[Hg]S
2026-10-28Heart rate70/minS
2026-10-28Respiratory rate14/minS
2026-10-28Body temperature36.6CelS
2026-10-28Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-28Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-10-28Creatinine [Mass/volume] in Serum or Plasma1.02mg/dL0.74-1.35 mg/dLNormalS
2026-10-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M96mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-28Hemoglobin A1c/Hemoglobin.total in Blood5.5%<=5.6%NormalS
2026-10-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L7-55 U/LNormalS
2026-10-28Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L8-48 U/LNormalS
2026-10-28Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma55U/L8-61 U/LNormalS
2026-10-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-10-28Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Physical Exam

Vital signs recorded on 2026-10-28; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 122/78, pulse 70; weight 102.6 kg, BMI 30.6
NeckCircumference 42 cm
NeurologicalNo tremor or sedation

Problems

ProblemClinical statusVerificationCodeProvenance
Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readingsresolvedconfirmed R53.83S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses.
Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped workingactiveconfirmed E66.811S — Synthetic modern diagnosis anchored to his documented weight gain.
Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoidedactiveconfirmed H40.63X1S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes.
Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillersactiveconfirmed F11.20S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis.
Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedativesactiveconfirmed F13.20S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis.
Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normalactiveconfirmed I10S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension.
Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAPactiveconfirmed G47.33S — Synthetic modern diagnosis from a synthetic sleep study.
Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm featuresactiveconfirmed K59.03S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon.
Acute low back strain after karate practice, without radicular signs or red flags, in a man on buprenorphine; resolvedresolvedconfirmed S39.012AS — Synthetic acute injury; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, withdrawal symptoms, cravings and other opioid useEvery four weeks once stableCompleted today16 mg daily; no other opioid; rare cravings
SurveyWeekly video visits while awayWeekly during engagements and toursCompleted todayAll three weekly visits on tour kept at the fixed time
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's prescriptions
LaboratoryUrine drug test, including buprenorphine metabolite and fentanylAt the start of treatment, then about monthly while doses are changingCompleted todayBuprenorphine, norbuprenorphine and benzodiazepines present; no other opioid; fentanyl absent (narrative)
Medication safetyNaloxone on hand and people taught to use itEvery visitCompleted todayOn hand at home and in the tour bag
Medication safetyDiazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper paceEvery two to four weeks during the taperCompleted today32 to 30 mg a day (6%) after five weeks at 32 mg; no withdrawal symptoms
SurveySuicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; firearms and medicines locked
SurveyMood (PHQ-9) and anxiety (GAD-7)At each reviewCompleted todayPHQ-9 4 (item 9 scored 0); GAD-7 5
ExaminationOffice and home blood pressure (target below 130/80)Every visitCompleted todayOffice 122/78; home average 122/78
LaboratoryPotassium and creatinine after starting an angiotensin receptor blockerTwo to four weeks after starting, then every six monthsCompleted todayPotassium 4.3, creatinine 1.02
LaboratoryHemoglobin A1c in prediabetesEvery three to six months during treatmentCompleted today5.5%, from 5.8%
LaboratoryLiver tests (ALT, AST, GGT)Three to six months after an abnormal resultCompleted todayALT 44, AST 33, GGT 55 U/L, all normal, from 72, 52 and 78
ExaminationWeight and BMIEvery visitCompleted today102.6 kg, BMI 30.6; down 6.4 kg
Medication safetyTirzepatide tolerance: nausea, vomiting, constipation, abdominal painAt each dose stepCompleted today5 mg for five weeks: nausea once; no vomiting or constipation
SurveyCPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)Within the first 30 to 90 days, then at each reviewCompleted today88% of nights; Epworth 6
Self-managementBowel frequency, straining and alarm featuresEvery visitCompleted todayDaily or every other day
ExaminationGlaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-upEvery visit; ophthalmology every three to six months while recently controlledCompleted todayNo eye symptoms; drops nightly; next ophthalmology visit in three to six months

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), second of two doses [S]

Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022); Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (2024); Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, hypertension, glaucoma, and depression, bipolar, and mood disorders monographs (2026)

Follow-up: Second hepatitis B vaccine dose given today. Review in four weeks with the next taper step; influenza vaccine then. [S]